We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Finger Prick Test Could Predict COVID-19 Complications from Drop of Blood

By LabMedica International staff writers
Posted on 12 Sep 2022
Print article
Image: New technology is being designed to detect severe COVID complications such as thrombosis (Photo courtesy of Pexels)
Image: New technology is being designed to detect severe COVID complications such as thrombosis (Photo courtesy of Pexels)

Many people died from COVID-19 because of the rapid development of complications caused by the so-called immune system-induced cytokine storm during which the body releases too many inflammatory proteins called cytokines into the blood too quickly. Symptoms include high fever, severe fatigue and sometimes organ failure. A cytokine storm can lead to abnormal blood clotting through the body’s blood vessels. For COVID-19 patients, it can lead to complications that contribute to respiratory difficulties and ultimately cause the patient’s death. But could some of those who died from COVID-19 and other infectious diseases have been saved by a diagnosis that predicts how severe their cases will be and provides timelier treatment?

An interdisciplinary team of engineers and doctors at Tulane University (New Orleans, LA, USA) hopes to answer that question with the development of new technology designed to detect severe COVID complications such as thrombosis, a condition in which blood clots block veins and arteries. The team has received a nearly USD 600,000 Trailblazer Award from the National Institute of Biomedical Imaging and Bioengineering to take on research that will lead to tests that can predict the severity of infectious diseases. The goal is to develop a diagnostic test that uses a drop of blood from a finger prick – a test that could be performed at a hospital, in a clinic or at home.

“Many patients who died from COVID-19 and other infectious diseases developed severe thrombotic complications shortly after disease symptoms were manifested,” said Damir Khismatullin, PhD, an associate professor of biomedical engineering in the Tulane School of Science and Engineering. “Their lives could be saved by predictive diagnosis of disease severity and timely treatment. However, tests that effectively predict the severity of infectious diseases are not available yet.”

Related Links:
Tulane University

Gold Supplier
SARS-CoV-2 Control
VIROTROL SARS-CoV-2 (IVD/CE Mark)
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
New
Silver Supplier
MDF-U731M-PE Biomedical -30°C Freezer
PHCbi MDF-U731M-PE
New
Human Anti-S. Cerevisiae Antibodies Test
ASCA-CHEK

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.